Inmune Bio Inc. (NASDAQ: INMB) announced on October 27, 2026, the execution of a securities purchase agreement with a single healthcare-focused institutional investor. The transaction consists of a registered direct offering and a concurrent private placement.
Under the terms of the agreement, the Company agreed to sell 3,000,000 shares of common stock at a price of $1.50 per share. Concurrently, the Company issued unregistered warrants to purchase an additional 3,000,000 shares of common stock. The total expected gross proceeds from the transaction are $4.50 million, before deducting placement agent fees and offering expenses.
The closing of the Offering is scheduled for October 29, 2026, subject to customary closing conditions. The Company intends to use the net proceeds for working capital purposes and general corporate procedures.
The common stock was offered pursuant to an effective shelf registration statement on Form S-3 (File No. 333-279036). The private placement of the warrants and underlying shares was conducted under an exemption from registration provided by Section 4(a)(2) of the Securities Act.
A.G.P./Alliance Global Partners has been engaged as the sole placement agent for the transaction on a "reasonable best efforts" basis. The Company agreed to pay the agent a cash fee equal to 7.0% of the gross proceeds, along with reimbursement for legal expenses up to $100,000 and non-accountable expenses up to $25,000.
The unregistered warrants have an exercise price of $1.65 per share. They become exercisable on April 27, 2027, and will expire on April 27, 2032. The Company has agreed to file a registration statement on Form S-1 to facilitate the resale of the warrant shares within 30 days of the closing date.
